EPO DTC Ads Create Impression Unsupported By Data, FDA And ODAC Agree
Executive Summary
FDA and the experts on its Oncologic Drugs Advisory Committee alike have been troubled by the way that unchecked direct-to-consumer advertising of erythropoiesis-stimulating agents has created a favorable impression of the anemia therapies that is not supported by available data
You may also be interested in...
EPO Dosing Questions Left Unanswered; More Data, More Meetings Needed
Amgen does not currently have enough data to characterize the relationship between targeted hemoglobin levels in patients receiving erythropoiesis-stimulating agents and clinical outcomes in the oncologic setting
EPO Scathed But Survives ODAC Challenge; Cmte. Calls For Additional Trials
Sponsors of erythropoiesis-stimulating agents should conduct additional safety studies to support continued marketing in the oncology setting, FDA's Oncologic Drugs Advisory Committee unanimously recommends
Amgen, J&J Barred From Marketing Procrit, Aranesp Chemo-Anemia Benefit
Amgen and Johnson & Johnson are no longer able to promote the impact of their respective erythropoiesis-stimulating agents Aranesp and Procrit on symptoms of anemia in cancer patients, FDA said